Compass Therapeutics, Inc. $CMPX Shares Sold by Monashee Investment Management LLC

Monashee Investment Management LLC lessened its stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 20.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,000,000 shares of the company’s stock after selling 250,000 shares during the period. Compass Therapeutics accounts for about 3.0% of Monashee Investment Management LLC’s holdings, making the stock its 14th biggest holding. Monashee Investment Management LLC’s holdings in Compass Therapeutics were worth $5,370,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in CMPX. Suvretta Capital Management LLC increased its stake in shares of Compass Therapeutics by 97.2% during the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock valued at $49,354,000 after acquiring an additional 6,951,666 shares during the period. Vivo Capital LLC grew its position in Compass Therapeutics by 57.9% in the third quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock worth $33,409,000 after buying an additional 3,502,000 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in Compass Therapeutics in the third quarter worth approximately $9,892,000. Millennium Management LLC grew its position in Compass Therapeutics by 280.4% in the third quarter. Millennium Management LLC now owns 3,237,572 shares of the company’s stock worth $11,332,000 after buying an additional 2,386,367 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Compass Therapeutics by 45.6% in the third quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock worth $24,720,000 after buying an additional 2,212,794 shares during the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Stock Performance

NASDAQ CMPX opened at $2.01 on Friday. Compass Therapeutics, Inc. has a twelve month low of $1.61 and a twelve month high of $6.88. The stock has a market cap of $361.98 million, a price-to-earnings ratio of -4.90 and a beta of 0.89. The firm’s 50 day moving average price is $3.24 and its two-hundred day moving average price is $4.78.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). On average, research analysts forecast that Compass Therapeutics, Inc. will post -0.42 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on CMPX shares. D. Boral Capital restated a “buy” rating and issued a $30.00 price target on shares of Compass Therapeutics in a research report on Monday, April 27th. Cantor Fitzgerald restated an “overweight” rating on shares of Compass Therapeutics in a research report on Thursday, March 12th. Citigroup restated a “market outperform” rating on shares of Compass Therapeutics in a research report on Thursday, June 4th. Raymond James Financial lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 28th. Finally, HC Wainwright restated a “buy” rating and issued a $24.00 price target on shares of Compass Therapeutics in a research report on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $12.91.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.